Cell & gene therapy
11 articles
China proposes curbs on foreign acquisitions of critical biopharma technologies
- China is proposing new restrictions on foreign acquisitions of critical biopharma technologies as it seeks to keep control of its fast-growing drug development industry.
- Trade coverage of the draft (Fierce) describes it as targeting full transfers of proprietary cell and gene therapy, siRNA and pathogen gain-of-function platforms, while standard out-licensing and CRO/CDMO outsourcing appear to be exempt.
- The final text and timing are not confirmed.
If licensing really stays exempt, the draft mostly shuts the door on buying a Chinese platform company outright while leaving the license-in model that Western pharma has leaned on intact. That nudges deal structure toward options and NewCo licensing, not away from China. Buyers of cell, gene and siRNA platforms are the ones who should re-run their pipelines of targets.
STAT+: China moves to restrict foreign biotech acquisitions ↗
Lakefront offloads its shelved CAR-T pipeline to Stoffels-backed Armed Cell
- Lakefront Biotherapeutics, the former Galapagos, is selling its abandoned cell therapy programs to Armed Cell Therapeutics, a new Belgian company co-founded and chaired by ex-Galapagos CEO Paul Stoffels.
- Reported terms are a small upfront payment (single-digit millions of euros) plus up to roughly $230 million in milestones.
- The package covers two armed CAR-Ts nearing the clinic in non-Hodgkin lymphoma and small cell lung cancer, plus three early preclinical projects.
A tiny upfront against a long milestone tail is what a buyer pays for preclinical assets nobody else wanted: the risk stays with Armed Cell, and Lakefront gets optionality without cost. For Lakefront, the signal is a clean pivot to autoimmune T-cell engagers. The open question is whether Armed Cell, run by the man who started the CAR-T bet, can fund the clinic.
Rebranded Galapagos finally finds buyer for unwanted cell therapy pipeline ↗
Caribou Biosciences winds down after failing to fund late-stage CAR-T trial
- STAT reports the Doudna co-founded company is shutting down after failing to raise the money needed for a late-stage trial of its off-the-shelf CAR-T therapy for lymphoma.
- Other coverage describes the company stopping development of its two clinical cell therapy candidates and cutting most staff while exploring a merger or sale.
- Only the public STAT+ summary was available, so details beyond that are unverified.
A flagship CRISPR-era CAR-T name folding over a funding gap says the off-the-shelf cell therapy thesis is struggling to raise money against autologous products and bispecifics. It reads more as a financing failure than a clean scientific verdict, so watch whether the assets and data find a buyer.
STAT+: Caribou Biosciences, biotech co-founded by Jennifer Doudna, is shutting down ↗
Basecamp Research Raises $140M to Power New AI Biology Models
- Basecamp Research, a London-based AI drug design startup, closed an oversubscribed $140M Series C led by S32 at an ~$800M valuation, with Nvidia, Anthropic's Anthology Fund and other investors participating.
- Funds will train next-generation EDEN foundation models built on the firm's proprietary environmental and biodiversity genomic dataset.
- The financing advances a pipeline of AI-designed therapeutics, starting with in vivo cell therapies, toward clinical development.
Basecamp isn't training on the same public protein databases every AI-discovery rival uses — its moat is proprietary environmental and biodiversity genomics, genuinely hard to replicate, worth more than the $800M valuation headline. Nvidia and Anthropic both backing one biology-foundation-model shop reads as infrastructure players staking platform claims on bio FMs, and opening the pipeline with in vivo cell therapy instead of small molecules is a far riskier first bet to prove the thesis in clinic.
AI startup Basecamp Research raises $140M Series C, shares pipeline ↗
Lexeo Expands Friedreich's Ataxia Pipeline With Mantle Buyout
- Lexeo Therapeutics agreed to acquire Mantle Therapeutics for up to $21.3 million, adding four frataxin-targeting Friedreich ataxia programs to its AAV gene therapy pipeline.
- Early data on the lead acquired asset in a small patient cohort showed a meaningful improvement on a standard ataxia rating scale.
- Lexeo also struck new research collaborations with Weill Cornell Medicine, Vivet Therapeutics, and Apertura Gene Therapy to pursue CNS-penetrant treatment approaches.
At $21.3M this is pocket change next to Telix-ITM, but strategically it's the smarter bolt-on: Lexeo already runs an AAV cardiac program in Friedreich's ataxia, so four more frataxin-targeting assets plus fresh CNS-penetrant collaborations with Weill Cornell, Vivet, and Apertura consolidate it as the depth player in a disease few large-caps are chasing.
Lexeo takes up the Mantle in $8M acquisition for Friedreich ataxia assets ↗
Ultragenyx Wins FDA Nod for First Sanfilippo Syndrome Gene Therapy
- The FDA granted full approval on September 17, 2026 to FAYUVI (rebisufligene etisparvovec-hopf, also known as UX111), an AAV-based gene therapy developed by Ultragenyx.
- FAYUVI is indicated for pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA), or Sanfilippo syndrome Type A — a progressive, fatal neurodegenerative disorder sometimes called "childhood Alzheimer's" that causes developmental delay followed by loss of cognitive, language, and motor function.
- It is the first-ever FDA-approved treatment for Sanfilippo syndrome Type A and represents Ultragenyx's second approved gene therapy overall.
- The approval qualified Ultragenyx for a Priority Review Voucher.
- Commercial product is expected to begin shipping to Qualified Treatment Centers within 30 to 60 days.
Second AAV gene therapy approval in Ultragenyx's stable is the real headline here — it validates a repeatable regulatory and manufacturing playbook for ultra-rare CNS disease, not a one-off. That de-risks the rest of the pipeline (other MPS subtypes, Angelman, etc.) in investors' eyes far more than the Sanfilippo indication itself. The Priority Review Voucher is worth watching separately: PRVs have changed hands for $100M+ in recent years, so this is a monetizable balance-sheet asset Ultragenyx can sell or redeem, not just a regulatory footnote. On revenue, ultra-rare gene therapies typically carry seven-figure list prices against a tiny diagnosed population — expect a slow, lumpy ramp gated by Qualified Treatment Center onboarding and payer negotiations rather than the 30-60 day shipping window. No approved or late-stage competitor targets MPS IIIA specifically, so Ultragenyx effectively owns this niche outright — for now.
FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease ↗
Longeveron's Stem Cell Therapy Fails Pediatric Heart Trial, Triggers Cost Cuts
- Longeveron's Phase 2b ELPIS II trial tested laromestrocel, a mesenchymal stem cell therapy, as an add-on to Stage 2 palliative surgery in 40 infants with hypoplastic left heart syndrome (HLHS), a rare, severe congenital heart defect.
- The trial missed its primary endpoint: at 12 months, right ventricular ejection fraction did not improve meaningfully in treated infants versus controls.
- No new safety signals emerged; treated infants had numerically fewer deaths than controls over 12 months — reassuring, but not a substitute for the missed efficacy signal.
- Following the miss, Longeveron said it will cut costs, is "exploring all options" for the program and company strategy, and plans further FDA discussions.
- Shares fell sharply in premarket trading after the announcement.
This is another entry in cell therapy's uneven ledger: mesenchymal stem cell candidates have repeatedly stumbled in small, underpowered pediatric and rare-disease trials, and a 40-patient study was never going to generate a statistically bulletproof efficacy case either way. The "numerically fewer deaths" framing is a familiar move — a directionally encouraging but non-significant number, worth reading as reassurance on safety, not as a rescue for the missed primary endpoint. More telling is the language around cost cuts and "exploring all options": for a small-cap with a thin, concentrated pipeline built largely around laromestrocel, that's the standard prelude to a strategic pivot — partnering out remaining assets, a reverse merger, or a slow wind-down — rather than business as usual. Investors should expect the MSC therapy category's credibility gap with capital markets to widen further on this news.
Longeveron's phase 2b stem cell flop spurs cost cutting, exploration of 'all options' ↗
Encoded Therapeutics Raises $275M Series F for Dravet Syndrome Gene Therapy
- Encoded Therapeutics closed a $275 million Series F financing round, co-led by GV and an undisclosed healthcare investor, with participation from ARCH Venture Partners, Braidwell, Farallon, Illumina Ventures, Invus, Janus Henderson, Matrix Capital, RTW Investments, SoftBank Vision Fund 2, Venrock and others.
- Proceeds will fund pivotal and age-expansion studies of ETX101, an AAV9-delivered gene-regulation therapy designed to restore SCN1A gene expression in children with SCN1A-positive Dravet syndrome, a severe and treatment-resistant form of pediatric epilepsy.
- Interim data from the Phase 1/2 POLARIS trial, presented at the European Epilepsy Congress, showed encouraging reductions in seizure frequency and gains on developmental measures among treated children.
- The financing will also support manufacturing scale-up and advancement of a second pipeline program, ETX301, targeting post-amputation neuroma pain, toward an IND filing in 2027.
Two hundred seventy-five million is a lot of private capital for a single indication, and it's flowing into gene regulation, not editing or replacement — investors betting that tunable, reversible expression control beats permanent genomic rewrites for a pediatric CNS target. The POLARIS interim data give Encoded first-mover clinical standing in SCN1A-directed Dravet therapy, ahead of gene-replacement and antisense rivals still in earlier stages. The size and syndicate here — GV, ARCH, SoftBank Vision Fund 2 — also reads as a financing-market tell: late-stage private mega-rounds are absorbing capital that might otherwise chase an IPO, a sign the window stays selectively closed. Earmarking part of the raise for ETX301, an unrelated pain asset, is a platform bet — diversification that could dilute focus on the pivotal Dravet push.
TScan Guts 75% of Staff, Shelves Blood Cancer and Autoimmune Programs to Chase Solid Tumors
- TScan Therapeutics is pausing enrollment in its Phase 3 ALLOHA-2 trial of TSC-101, an allogeneic TCR-T therapy for blood cancers, citing insufficient funding to finish the study.
- The seven patients already dosed will keep being monitored; the company is now shopping the heme program to potential partners.
- TScan is also pausing its autoimmunity work, including its HLA-B*27 program in ankylosing spondylitis, while seeking outside partners for it as well.
- The company is cutting roughly 75% of its workforce and shutting down internal manufacturing to redirect resources toward its preclinical in vivo TCR-T platform for solid tumors.
- Management expects about $55 million in savings, pushing its cash runway out into Q4 2027.
Shelving a Phase 3 asset with seven patients already dosed — not a preclinical program — tells you where the real cash crunch sits. This isn't routine reprioritization; it's a company admitting it can't fund its most advanced bet to the finish line, however the release frames it. The pivot to in vivo TCR-T for solid tumors is bet-the-company: trading a derisked clinical program for an earlier-stage platform nobody has yet proven works in vivo. High conviction, but also a tacit admission the allogeneic heme franchise found no partner willing to bankroll it. Allogeneic TCR-T for blood cancers has gotten capital-intensive with thin differentiation between competitors — expect more heme/autoimmune cell-therapy assets to hit the partnering block as smaller players run short of runway before readouts. Reaching only Q4 2027 after cutting 75% of headcount suggests the burn problem was structural, not confined to the heme program.
TScan axes 75% of workforce to make room for solid tumor programs ↗
uniQure Submits FDA BLA and UK MAA for Huntington's Gene Therapy AMT-130
- uniQure submitted a Biologics License Application (BLA) to the FDA for ifezuntirgene inilparvovec (AMT-130), an AAV gene therapy for Huntington's disease, and requested Priority Review.
- The company also filed a parallel Marketing Authorisation Application (MAA) with the UK's MHRA.
- AMT-130 targets the underlying genetic cause of Huntington's disease and would be the first such therapy to reach approval if cleared.
- The filings are supported by a three-year Phase I/II data analysis using a propensity-score-matched external control group from the Enroll-HD natural history database, since the trial has no concurrent placebo arm — a closely watched test of gene-therapy approval without randomized controls.
- The submission follows earlier FDA pushback on the data package before the agency aligned with uniQure; AMT-130 already holds Breakthrough Therapy, RMAT, and Fast Track designations.
First-mover matters more than usual here: Wave's WVE-003 and PTC's PTC518 are both earlier-stage, so a clean AMT-130 approval buys uniQure a real multi-year head start — once a Huntington's patient gets a one-time AAV infusion, there's no switching later. The external-control strategy is the real story though. FDA reportedly pushed back before coming around, so this reads as a precedent still being negotiated in real time, not a settled template — a green light here would embolden every small-N gene therapy sponsor; a post-approval stumble (Sarepta's the cautionary comp) would make uniQure the counterexample instead. Priority Review is less validation of the science than a compressed timeline for a single-asset story that's had its own FDA whiplash — the shorter clock is the real de-risking event for the stock, not proof the data holds up long-term.
Pharmalittle: UniQure submits Huntington's gene therapy to FDA ↗
Novartis and BMS Pause Autoimmune CAR-T Trials After Safety Events
- Novartis and Bristol Myers Squibb separately paused clinical trials of experimental autologous CAR-T cell therapies being developed for autoimmune and neurological conditions, including lupus, rheumatoid arthritis, vasculitis, multiple sclerosis and myasthenia gravis.
- Novartis halted eight studies of its candidate, rap-cel (rapcabtagene autoleucel), around August 24 after three patients died from immune effector cell-associated hemophagocytic syndrome (IEC-HS), a severe systemic inflammatory reaction.
- Bristol Myers Squibb paused enrollment in trials of its own CD19-targeted CAR-T, zola-cel, describing "transient and reversible inflammatory events" markedly less severe than the deaths Novartis reported, and saying the therapy's safety profile otherwise remains consistent with other CAR-T treatments.
- Both companies said they are reviewing clinical data with independent safety boards and regulators before deciding on next steps for their affected programs.
Autoimmune CAR-T was the industry's hottest oncology-to-new-indication pivot — Kyverna, Cabaletta, Autolus and multiple academic programs are all racing the same CD19 mechanism, so this becomes a class-level scrutiny event, not just a Novartis/BMS problem. The two signals aren't equivalent: three IEC-HS deaths is a materially different regulatory conversation than BMS's "reversible" events — expect FDA to treat rap-cel far more cautiously than zola-cel, even though headlines pair them. Multi-trial pauses cost both companies precious time on programs meant to diversify beyond their legacy oncology CAR-T franchises (Kymriah, Breyanzi) into a much larger chronic-disease market. If regulators respond with class-wide holds or REMS-style safeguards, smaller autoimmune CAR-T players inherit the delay and diligence burden without the balance sheets to absorb it.
UPDATED: Novartis halts autoimmune CAR-T trials after 3 deaths, as BMS also pauses studies ↗